| Original language | English (US) |
|---|---|
| Pages (from-to) | 277-279 |
| Number of pages | 3 |
| Journal | JAMA cardiology |
| Volume | 3 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2018 |
Funding
For US-based genetic testing, African American individuals and most Latino/Hispanic groups are not adequately represented. Efforts like the National Heart, Lung, and Blood Institute’s Trans-Omics for Precision Medicine,9 the All of Us Research Program10 of the National Institutes of Health, and the Million Veteran Project11 of the US Veterans Administration are aimed at better representing the US population. The data that will be ultimately available from these projects will be deposited into publicly accessible databases. Important caveats to these data sets are a lack of individual-level data and completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr McNally received support from the National Institutes of Health in support of this work, as well as grants from the American Heart Association, Solid Biosciences, Parent Project Muscle Dystrophy, and the US Department of Defense, outside the submitted work. Dr McNally is also a consultant to Novartis, Pfizer, AstraZeneca, Mitobridge, Invitae, Summitplc, Exonics, Eli Lilly & Company, and Fibrogen. No other disclosures are reported.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine